Clinical Trials · NCT03112694

Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

Name: Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedN/AOctreotide Lanreotide

Phase: N/A
Recruitment status: Completed
Sponsor: Ipsen
Enrollment: 93
Start date: Apr 2017
Locations: 8 sites, United States
Primary endpoint: Response to treatment

View Octreotide compound reference